全国培训与随机试验后微创远端胰腺切除术的IDEAL IV期应用与结局
该全国性审计研究纳入荷兰16个中心2014至2021年连续行微创或开放远端胰腺切除术的患者共1496例,其中微创848例(56.5%)、开放648例(43.5%)。微创使用率从早期48.6%升至晚期63.0%,机器人微创从5.5%升至29.7%(P<0.001),各中心间差异显著;微创术后住院更短、出血更少,但B/C级胰瘘更多。
要点
- 培训与随机试验后微创远端胰腺切除术在全国范围持续开展,结局稳定。
- 晚期微创使用率达63.0%,机器人微创升至29.7%,但中心间差异大。
- 微创术后住院更短、出血更少,但B/C级胰瘘发生率更高。
核心结论
- 在成功培训项目和随机试验后,微创远端胰腺切除术获得了持续的全国性实施,且结局令人满意。
- 未来研究应评估各中心间微创使用率尤其是机器人微创使用率的显著差异。
研究设计与样本
- 基于全国审计的研究,纳入荷兰胰腺癌审计中16个中心2014至2021年连续接受微创或开放远端胰腺切除术的患者。
- 共纳入1496例患者,其中微创远端胰腺切除术848例(56.5%),开放远端胰腺切除术648例(43.5%)。
- 队列分为三个时期:早期实施期、LEOPARD随机试验期间和晚期实施期。
- 主要终点为微创远端胰腺切除术实施率和教科书结局。
主要发现
- 从早期到晚期实施期,微创远端胰腺切除术使用率从48.6%增至63.0%,机器人微创从5.5%增至29.7%(P<0.001)。
- 各中心间微创总体使用率(45%至75%)和机器人微创使用率(1%至84%)差异很大(P<0.001)。
- 晚期实施期16个中心中有5个中心以微创完成超过75%的手术。
- 微创术后院内死亡率和教科书结局随时间保持稳定。
- 晚期实施期开放手术更多用于ASA III-IV级(24.9% vs. 35.7%,P=0.001)、胰腺癌(24.2% vs. 45.9%,P<0.001)、血管受累(4.6% vs. 21.9%,P<0.001)和多脏器受累(10.5% vs. 25.3%,P<0.001)患者。
临床怎么用
- 在完成培训并积累试验证据后,可将微创远端胰腺切除术作为常规术式持续开展。
- 选择微创时应权衡其缩短住院和减少出血的优势与B/C级胰瘘风险增加。
- 对ASA III-IV级、胰腺癌、血管或多脏器受累患者,开放手术仍较常被选用。
局限性
- 研究为基于全国审计的非随机设计,未报告随机对照比较。
- 各中心间微创及机器人微创使用率差异显著,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the nationwide long-term uptake and outcomes of minimally invasive distal pancreatectomy (MIDP) after a nationwide training program and randomized trial. BACKGROUND: Two randomized trials demonstrated the superiority of MIDP over open distal pancreatectomy (ODP) in terms of functional recovery and hospital stay. Data on implementation of MIDP on a nationwide level are lacking. METHODS: Nationwide audit-based study including consecutive patients after MIDP and ODP in 16 centers in the Dutch Pancreatic Cancer Audit (2014 to 2021). The cohort was divided into three periods: early implementation, during the LEOPARD randomized trial, and late implementation. Primary endpoints were MIDP implementation rate and textbook outcome. RESULTS: Overall, 1496 patients were included with 848 MIDP (56.5%) and 648 ODP (43.5%). From the early to the late implementation period, the use of MIDP increased from 48.6% to 63.0% and of robotic MIDP from 5.5% to 29.7% ( P <0.001). The overall use of MIDP (45% to 75%) and robotic MIDP (1% to 84%) varied widely between centers ( P <0.001). In the late implementation period, 5/16 centers performed >75% of procedures as MIDP. After MIDP, in-hospital mortality and textbook outcome remained stable over time. In the late implementation period, ODP was more often performed in ASA score III-IV (24.9% vs. 35.7%, P =0.001), pancreatic cancer (24.2% vs. 45.9%, P <0.001), vascular involvement (4.6% vs. 21.9%, P <0.001), and multivisceral involvement (10.5% vs. 25.3%, P <0.001). After MIDP, shorter hospital stay (median 7 vs. 8 d, P <0.001) and less blood loss (median 150 vs. 500 mL, P <0.001), but more grade B/C postoperative pancreatic fistula (24.4% vs. 17.2%, P =0.008) occurred as compared to ODP. CONCLUSION: A sustained nationwide implementation of MIDP after a successful training program and randomized trial was obtained with satisfactory outcomes. Future studies should assess the considerable variation in the use of MIDP between centers and, especially, robotic MIDP.
引用
- Korrel M, van Hilst J, Bosscha K, et al. Nationwide use and Outcome of Minimally Invasive Distal Pancreatectomy in IDEAL Stage IV following a Training Program and Randomized Trial. Ann Surg. 2023. PMID: 37139822. doi:10.1097/SLA.0000000000005900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。